Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma - sprookjes - yvandenbroek - TriplyDB

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

http://www.wikidata.org/entity/Q35902345

about

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer Therapy Advances in the autologous and allogeneic transplantation strategies for multiple myeloma Proteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancer Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer.The Fanconi anemia pathway and ICL repair: implications for cancer therapy.Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors Inactivating UBE2M impacts the DNA damage response and genome integrity involving multiple cullin ligases.Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.Upregulation of Fanconi anemia DNA repair genes in melanoma compared with non-melanoma skin cancer CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.Catching moving targets: cancer stem cell hierarchies, therapy-resistance & considerations for clinical intervention.Oxidative stress-associated protein tyrosine kinases and phosphatases in Fanconi anemia Bortezomib: friend or foe of hemolytic anemia?The NFκB pathway: a therapeutic target in glioblastoma.Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.Genomic instability in multiple myeloma: mechanisms and therapeutic implications.Targeting homologous recombination-mediated DNA repair in cancer.The Tao of myeloma.INPP4B-mediated DNA repair pathway confers resistance to chemotherapy in acute myeloid leukemia.Nucleotide excision repair is a potential therapeutic target in multiple myeloma.A peptide nucleic acid targeting nuclear RAD51 sensitizes multiple myeloma cells to melphalan treatment.Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma Suitable drug combination with bortezomib for multiple myeloma under stroma-free conditions and in contact with fibronectin or bone marrow stromal cells.VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma.Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells.New insights into redox response modulation in Fanconi's anemia cells by hydrogen peroxide and glutathione depletors.Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents.

P2860

Q26801593-08B8019C-38F0-4BAA-A098-C62E482F0FBF Q27014801-739D809B-30CA-4CB6-9652-38134C8A327F Q27307731-A84F2890-DEA7-415B-9FA8-E56B65A9A49A Q28477988-D058762D-F291-4BE7-970D-477B8E4A41AE Q28486021-8B9AE5CC-065C-49FE-BAD5-CC7D6641053D Q28544009-13E2068A-1D76-4FF5-A4B1-D3A764A81872 Q33648344-CC7B3E71-E62A-4A69-9C0C-76A8F404EFCF Q35000084-5C21D5DB-CF3E-495E-933C-DFE9769C7B0B Q35024542-0B1A6CC4-2B7B-4FB1-99BB-9412AD8C6B9A Q35142790-8249749D-CFEE-45A6-AA07-E6230A49B371 Q35207086-5E689ACF-9113-460B-915F-95A1C3464EE2 Q35214544-B37130E8-152F-413B-B2B8-B4BA26B7E816 Q35216289-A982201E-24D1-4D4B-ADED-90D0B559D66B Q35247381-82F18CF2-0DD0-4433-A600-0D4982CC6BD8 Q35579598-EE3848FA-BAF4-4388-B639-0D7C2B3849A7 Q35868171-56E1D43A-454D-4EDA-A5A8-35B12E703BD9 Q35907767-04002D65-1024-4E90-9B6F-F094D9804768 Q36413288-44A3D926-57A0-4221-992B-B1269DA2A156 Q36642951-8734F4D1-998E-4F45-B226-844B0AD60405 Q36711842-6D52BDE7-7BDF-48CD-896C-8D5D9132E376 Q37505517-ABDA172E-D65E-48E0-90D9-CE8F8E9D18FB Q37661508-086E4319-2B4C-4128-A30E-8B6CF6EB9BDD Q37716059-F1E8A337-4806-480B-8707-B1F08B9BB02E Q37766378-86067132-2233-42A0-B9A2-BC857D8A5F7A Q37928304-0D5583D6-A259-4A38-A90F-D4EDDF258E7C Q38095526-CF898345-0FFB-4718-8BF8-183EE3915E2F Q38115576-1CF6C864-1C86-439A-A2F0-BB054F18FDF4 Q38184667-7F0FF682-2744-4D65-B8C9-4A9104C858C4 Q38237360-2F673CFC-6898-4600-AD9B-4C14FB6483C3 Q38736981-FA7298AC-967C-46DF-917D-C3F1B250933D Q38739689-97927F32-048D-4B45-B9F5-682D9EB58812 Q38872621-3A6567BA-2A14-4C92-8065-F837287125EE Q38925256-4BD0485F-FA95-422C-9CE6-FA2725A6060E Q38967891-7BBE2CED-0CDA-427C-9261-5646AB5F9DA1 Q39007207-70AF0529-5040-414B-ADE5-A7A7A1E83A00 Q39103567-DFB8600A-10BB-45EA-A77D-EBB8091E5341 Q39111478-6DE2925D-39B8-4F67-800A-55DE0513A0CB Q39140011-D7A6076D-70C2-4FBC-8472-C51B541871BF Q39350013-A6B3FFE4-08B4-4462-9D84-B6C074E8730D Q39417419-45DAF21A-C390-4DB8-BA5D-BAF635265413

P2860

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

http://www.wikidata.org/entity/Q35902345

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

@ast

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

@en

type

label

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

@ast

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

@en

prefLabel

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

@ast

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

@en

P1433

Q35902345-8096A60E-DD0E-4CC3-9A30-E034684D97BF

P1476

Q35902345-D3C5C2C5-9114-422D-BB14-EC577E6C27AE

P2093

Q35902345-0A35F6B9-9235-4AF8-9390-FD81B57CEDE2

Q35902345-1FC6CC21-17FD-4346-B07A-67283CA1183F

Q35902345-25CA19AD-5583-420A-97A1-DE07DFB26A9A

Q35902345-394EE7DA-E472-4E60-8FF9-8382CFDF1226

Q35902345-69E93010-2FF5-4224-BD2A-9119DE753803

Q35902345-6EDFB0B6-EFDF-4D7E-9CD1-DC5A9AB5D48A

Q35902345-75DBB640-89A9-4AA2-8A6D-D02F4F4D6C5D

Q35902345-794F9F09-AE2B-4AE1-9670-A2F01345E579

Q35902345-9DBDA678-5D4C-42BB-B478-DE39382E4D0B

Q35902345-9ED32DDA-AAAD-42C9-914B-E9EC30C1A3DA

P2860

Q35902345-00A6B6D5-11BE-4127-B168-C4EAB38C83C5

Q35902345-05A27B4B-E065-4144-B92F-D74734380C7F

Q35902345-0876511B-7B2D-4239-AE8A-5299429B7669

Q35902345-12D330A1-DA7C-4AA3-9DF3-6BDB9AB5593E

Q35902345-16422E65-AD05-46D4-9477-A0C3DD890667

Q35902345-167E3735-C3C6-4AB2-9698-44112D6AD19A

Q35902345-3F4AEB8E-AE93-4203-9B11-A7E7020CC283

Q35902345-45999D84-E6B0-4BCE-9914-9C812104F8A7

Q35902345-4A5814EA-3642-49F2-B27E-FB9CFC14528B

Q35902345-53DB6B4E-AE76-4001-91C5-810225A3F709

P304

Q35902345-E7CF4958-71BE-4E05-B818-F75C7CC59F9C

P31

Q35902345-936C76F5-B280-4CC8-940D-B36F8C0DB486

P356

Q35902345-CACC45E3-3BC5-4CF7-A073-4F92E8A17003

P407

Q35902345-1032DBFE-B9FF-473C-9109-C1A3058CCDC2

P433

Q35902345-97609B91-9382-4960-AB11-DC8130CDA2E8

P478

Q35902345-ABAC7567-F558-49D0-998D-B4ABD444CE8D

P577

Q35902345-9EA493BA-F322-427A-97F0-56848A4CFE4C

P698

Q35902345-7AA92023-A1A1-42EA-A84C-53F1D2C874F1

P921

Q35902345-EF349943-A466-45F5-B938-B566EAFB095C

P932

Q35902345-C7284372-F2C1-4BBE-BD37-9263FAAE3380

P356

0008-5472.CAN-09-2616

P1433

Cancer Research

P1476

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma

@en

P2093

Alejandro Villagra

http://www.w3.org/2001/XMLSchema#string

Amer A Beg

http://www.w3.org/2001/XMLSchema#string

Danielle N Yarde

http://www.w3.org/2001/XMLSchema#string

David Boulware

http://www.w3.org/2001/XMLSchema#string

Dung-Tsa Chen

http://www.w3.org/2001/XMLSchema#string

Kenneth H Shain

http://www.w3.org/2001/XMLSchema#string

Linda Mathews

http://www.w3.org/2001/XMLSchema#string

Lori A Hazlehurst

http://www.w3.org/2001/XMLSchema#string

Melissa Alsina

http://www.w3.org/2001/XMLSchema#string

Vasco Oliveira

http://www.w3.org/2001/XMLSchema#string

P2860

The Fanconi anaemia group G gene FANCG is identical with XRCC9

Isolation of a cDNA representing the Fanconi anemia complementation group E gene

FANCI is a second monoubiquitinated member of the Fanconi anemia pathway

Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene

A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M

Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair

The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM

Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors

P304

9367-9375

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-2616

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19934314

http://www.w3.org/2001/XMLSchema#string

P921

multiple drug resistance

P932

4519834

http://www.w3.org/2001/XMLSchema#string